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Objectives This study evaluated 3 novel questions in a prospective clinical cohort of women undergoing evaluation for sus-
pected myocardial ischemia: 1) What is the relationship between depression and cardiovascular costs? 2) Does
the relationship vary by definition of depression? 3) Do depression-cost relationship patterns differ among
women with versus without coronary artery disease (CAD)?
Background Comorbid depression has been linked to higher medical costs in previous studies of cardiovascular patients.
Methods A total of 868 women presenting with suspected myocardial ischemia completed an extensive baseline ex-
amination including cardiovascular risk factor assessment and coronary angiogram. Depression was de-
fined by: 1) current use of antidepressants; 2) a reported history of depression treatment; and 3) Beck De-
pression Inventory scores. Direct (hospitalizations, office visits, procedures, and medications) and indirect
(out-of-pocket, lost productivity, and travel) costs were collected through 5 years of follow-up to estimate
cardiovascular costs.
Results Using the study criteria, 17% to 45% of the women studied met study depression criteria. Depressed women
showed adjusted annual cardiovascular costs $1,550 to $3,300 higher than nondepressed groups (r  0.08 to
0.12, p  0.05). Depression-cost relationships also varied by CAD status, with stronger associations present
among women without evidence of significant CAD.
Conclusions Depression was associated with 15% to 53% increases in 5-year cardiovascular costs, and cost differences were
present using 3 definitions of depression. The results reinforce the importance of assessing depression in clinical
populations and support the hypothesis that improved management of depression in women with suspected
myocardial ischemia could reduce medical costs. (J Am Coll Cardiol 2009;53:176–83) © 2009 by the
American College of Cardiology Foundation
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January 13, 2009:176–83 Depression and Health Care Costsepression is a common and debilitating condition in the
.S., with widespread effects on health, quality of life, and
he economy (1–5). Health risks associated with depression
nclude premature mortality, cardiovascular disease (CVD),
mmune system suppression, sleep impairment, and higher
ates of drug abuse, among many others (6–10). Estimates
f the economic impact of depression in the U.S. range from
20 to $45 billion annually (11–13), rivaling those of
hronic diseases such as hypertension and osteoarthritis
14). Depression may also combine with chronic diseases
o increase health care costs. Among medical cohorts, for
xample, patients with conditions such as congestive
eart failure, diabetes, and coronary artery disease (CAD)
ho also suffered from depression were shown to have
arger health expenses compared with those without depres-
ion (15–19). Even minor depression increases economic
urden (20).
Women are diagnosed with depression at more than
wice the rate of men (21), suggesting that investigations of
epression and health care costs should include a strong
ocus on women. The aim of the current study is to describe
he relationship between depression and health care costs in
5-year prospective investigation of women with suspected
yocardial ischemia. Specifically, this report addresses the
ollowing questions:
. What is the relationship between depression and car-
diovascular costs?
. Does the relationship vary by definition of depression?
. Are depression-cost relationships similar across women
with and without evidence of CAD?
ethods
articipant recruitment and entrance criteria. Women
ere eligible for participation in the WISE (Women’s
schemia Syndrome Evaluation) study if they were older
han age 18 years and were referred for a coronary angio-
ram to evaluate suspected myocardial ischemia (22). The
ISE study was designed to improve the understanding
nd diagnosis of ischemic heart disease in women. Exclu-
ion criteria included current pregnancy, cardiomyopathy,
ecent myocardial infarction or revascularization procedure
percutaneous coronary intervention, coronary artery bypass
raft), history of congenital heart disease, and a language
arrier preventing questionnaire completion. This report
ncludes data on 868 women with complete information on
ntidepressant use, depression treatment history, and indi-
ators used to calculate cardiovascular cost estimates. A
maller number (654 women) were available for analyses
ith the Beck Depression Inventory (BDI) due to a lagged
mplementation of the questionnaire measures into the
ISE study protocol. All participants provided written
nformed consent, and institutional review board approval
as obtained for all participating sites. peasurement of CAD and
linical outcome events. Quan-
itative analysis of coronary an-
iograms was performed offline
t the WISE Angiographic Core
aboratory (Rhode Island Hos-
ital, Providence, Rhode Island)
y investigators blinded to all
ther subject data (23). Luminal
iameter was measured at all ste-
oses and at nearby reference segments using an electronic
ine projector-based “cross-hair” technique (Vanguard In-
trument Corporation, Melville, New York). Using the
ngiogram results, each participant was assigned a contin-
ous CAD severity score based on a modified Gensini index
23). Significant CAD was defined as a maximum stenosis
alue 50% (22).
ardiovascular-related events and cost estimates. Infor-
ation concerning CVD events, hospitalizations, and med-
cation use was collected at 6 weeks after baseline and
nnually thereafter by means of a scripted interview (24).
uring the interview, information regarding the occurrence
f outpatient procedures, hospitalizations, and clinic visits
o physician extenders, generalists, and specialists was col-
ected. This data collection tool was previously validated
gainst verified events (24). The CVD events included
troke, congestive heart failure, and myocardial infarction.
ource documentation was not obtained for office visits. In
he event of death, a death certificate was obtained.
ost accounting methods. Details of the cost methods
ere previously published (25). In brief, we used a hybrid
ost model (including hospital-specific and published
osts as inputs) for cases in which patient bills were not
vailable. In this model, we used extensive prior pub-
ished reports on procedural and hospital costs as well as
ost estimates from national and regional average proce-
ural and hospital charges (adjusted by state-specific
ost-charge ratios) (24,25). Hospitalization (for chest
ain, myocardial infarction, heart failure) and procedural
for coronary angiography, revascularization, stress car-
iac imaging) costs were obtained from published reports
24 –30). Cardiovascular drug costs were derived from the
003 Red Book (31). We performed numerous sensitivity
nalyses using a range of costs for procedures and
ospitalizations. We totaled 5-year and annual costs for
ardiovascular hospitalizations, coronary revasculariza-
ion and angiography, outpatient testing, and visits to
eneralists, specialists, nurse practitioners/physician’s as-
istants, or community clinics. Summed 5-year costs were
onsidered a measure of direct cardiovascular care costs
nd did not include costs for mental health care. Costs
ere discounted with the use of a 5% annual rate,
orrected for inflation by the U.S. medical service sector
stimate (city average) of the consumer price index (for
rban wage earners and clerical workers) (32). Each
Abbreviations
and Acronyms
BDI  Beck Depression
Inventory
CAD  coronary artery
disease
CVD  cardiovascular
diseaseatient’s out-of-pocket expenses (i.e., indirect costs) were
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Depression and Health Care Costs January 13, 2009:176–83lso collected by self-report (26,27). Indirect cost data
ere estimated for hours lost from work for health care,
stimated reduced productivity hours, transportation
osts, and out-of-pocket costs for drugs, medical devices
e.g., glucose meter), and alternative therapies (e.g.,
itamins). Patient self-reported income was used to esti-
ate indirect costs for lost productivity.
epression, socioeconomic status, and functional
apacity. Depression was quantified in 3 ways: 1) use of
ntidepressants within the week prior to study entry; 2) a
elf-reported history of depression requiring treatment; and
) completion of the BDI (33). The BDI is a validated
1-item questionnaire that has been linked to poor CVD
utcomes (34). Scores 10 on the BDI questionnaire are
ften used to indicate the presence of at least mild depres-
ion symptoms (34).
Education history served as an estimate of socioeconomic
tatus. Lower socioeconomic status was defined as a re-
orted education history of less than high school gradua-
ion. We used the Duke Activity Status Index questionnaire
o estimate functional capacity based on self-reported ability
o perform various activities that correlate with exercise
readmill results (35).
raditional CVD risk factors. Major CVD risk factors in
he WISE protocol included smoking (defined as current vs.
ormer or never smokers), history of dyslipidemia (yes/no),
istory of diabetes (yes/no), history of hypertension (yes/
o), elevated waist-hip ratio (yes/no), and physical activity
dichotomously coded per protocol). An elevated waist-hip
atio was defined using a value 0.85 consistent with the
efinition used for women in INTERHEART (A Study of
isk Factors for First Myocardial Infarction in 52 Countries
nd Over 27,000 Subjects) study (36). Physical activity was
valuated with the PEPI (Postmenopausal Estrogen-
rogestin Intervention) study questionnaire (37), a self-
eported estimate of average physical activity level at home,
ork, and leisure on a 4-point scale, ranging from inactive
o heavy activity. Women who marked none of the PEPI
uestionnaire items as either moderate or heavy were
onsidered physically inactive.
tatistical analyses. Descriptive statistics were compared
sing chi-square (proportions) and independent t tests
means). For descriptive purposes, women were divided into
roups based upon: 1) use/no use of antidepressants at
aseline; 2) history/no history of reported treatment for
epression; and 3) BDI scores 10/10. These groups
ere not exclusive; rather, each woman was evaluated for
ach depression definition and could fit more than 1
riterion. We also assessed BDI-cost relationships keeping
he BDI scores in raw (noncategorized) format to examine
DI effects without the loss of power known to result from
rtificially dichotomizing continuous variables. Cumulative
ardiovascular costs served as the primary outcome measure,
racked to either death or the 5-year follow-up point (25).
n the event of death, costs were accumulated to the date of
ncidence, which served as the participant’s final cost figure. de also included medication costs as a secondary outcome,
xpecting that this category would be more heavily con-
ounded with psychotropic use. Due to significant variable
kewing, we logarithmically transformed the cost and CAD
everity variables before the analyses.
Multivariate linear regression models were completed to
est associations between depression and CVD costs. Final
odels were adjusted for demographic factors, CVD risk
actors, anxiolytic and cardiovascular medications, Duke
ctivity Status Index scores, insurance, marital, and disabil-
ty status, and CAD severity scores (Table 1). Regression
esults were converted into r coefficients as a standardized
ffect size metric using the formula r  (t2/[t2  df]),
here df  degrees of freedom available for the analysis
866 for antidepressant and depression treatment history
esults, 652 for BDI analyses). An alpha level of 0.05 was
sed as the criterion for significance in all tests, and statistics
ere completed using SPSS version 15.0 (SPSS Inc.,
hicago, Illinois).
esults
mong 936 women participating in the WISE study, 868
ad valid depression treatment history, antidepressant use,
nd cardiovascular cost data (654 with BDI data). Table 1
escribes the WISE sample, including a breakdown of
emographic variables and CVD risk factors by depression
tatus. Depression was common in the WISE study, with
7.3% reporting use of antidepressants at baseline, 24.4%
ndorsing a history of treatment for depression, and 45.3%
f women scoring 10 on the BDI. Status on the BDI
orrelated modestly with the antidepressant (r  0.18, p 
.001) and depression treatment history (r  0.21, p 
.001), whereas antidepressant use and depression treat-
ent history overlapped more strongly (r  0.57, p 
.001). A total of 89 deaths occurred in the group over a
edian 5.9 years of follow-up.
Although significance patterns varied somewhat by de-
ression marker, depressed women tended to be older, had
oorer CVD risk factor profiles, reported lower functional
apacity on the Duke Activity Status Index, and indicated
ower rates of marriage and full-time employment and
igher rates of disability. Depressed women also had lower
ates of prescription drug coverage and spent a larger
ercentage of their income on health care expenses. Based
pon the CAD severity score, depressed women had statis-
ically less severe CAD but were more prone to cardiovascular
vents over follow-up. Depression was strongly related to
ombined death and CVD event risk, with elevated BDI scores
relative risk [RR]: 1.7, 95% confidence interval [CI]: 1.2 to
.4), antidepressant use (RR: 2.2, 95% CI: 1.5 to 3.0), and
epression treatment history (RR: 2.0, 95% CI: 1.5 to 2.8),
ach reliable predictors after age and CAD severity score
djustment. Women missing BDI, depression treatment his-
ory, or antidepressant data did not differ from those with valid
epression information on factors listed in Table 1.
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January 13, 2009:176–83 Depression and Health Care Costsepression and health care costs. Figure 1 shows that
rends in depression-related cardiovascular cost differences
ere apparent as soon as year 1, with significant differences
merging by year 2 for the antidepressant (r  0.10, p 
.002) and depression treatment history (r  0.10, p 
.003) groups and by year 3 for those with higher BDI
cores (r  0.08, p  0.03). Translated into dollar figures,
nnual differences in cardiovascular costs were $3,200 (95%
I: $678 to $6,060), $3,300 (95% CI: $574 to $5,210), and
1,550 (95% CI: $143 to $4,056), for the antidepressant,
epression treatment history, and BDI groups, respectively,
ersus their nondepressed counterparts. Table 2 presents age
nd CAD severity score-adjusted cost differences. Costs for
epressed versus nondepressed women were significantly
igher for cardiovascular and medication cost categories. The
DI grouping produced smaller cost differences, which were
artly a result of the loss of power from dichotomizing the raw
uestionnaire scores. Using the continuous BDI scores as a
emographic and CVD Risk Factors Among Participants With/With
Table 1 Demographic and CVD Risk Factors Among Participant
Depression Treatment History
(n  868)
Yes
(n  228)
No
(n  640)
Age, mean (SD), yrs 55.3 (10.9) 59.2 (11.7)*
High school education 79.6 80.4
Caucasian 84.6 80.1
Using antidepressants 55.3 5.3*
Using anxiolytics 36.5 14.3*
Depression treatment history 100.0 0.0
Beck Depression Inventory 10 64.1 39.3*
Diabetic 23.8 25.2
Dyslipidemia 61.0 52.5*
Hypertensive 62.3 57.9
Physically inactive 37.2 30.6
Current smoker 31.1 16.7*
Waist-hip ratio 0.85 51.6 46.2
Using antihypertensive medications 50.2 57.8
Using lipid lowering medications 25.2 30.6
Duke Activity Status Index (mean) 16.0 (13.6) 21.5 (14.5)*
CAD severity score (mean) 12.5 (12.2) 15.4 (15.4)*
Married 58.3 64.0
Daily chest pain 42.3 36.8
Employed 21.9 26.5
Disabled 31.6 13.7*
Medical insurance 39.0 30.0*
Indirect costs† 9.3 12.2*
CABG 5.9 9.1
PTCA 18.6 15.4
Angiogram 30.4 27.7
Congestive heart failure 8.2 6.7
Myocardial infarction 6.4 2.8*
Stroke 5.0 4.8
Death 14.1 9.5*
alues are percentages unless otherwise indicated. Tests of proportions completed using chi-squa
f household income spent on health care.
CABG  coronary artery bypass graft; CAD  coronary artery disease; CVD  cardiovascular diseasure of depression symptom severity, each age and CAD beverity-adjusted point increase on the questionnaire was asso-
iated with a $670 increase in cardiovascular costs (r  0.11,
 0.005). Lastly, we also compared women based on their
umber of depression markers (range: 0 to 3), however, cost
ifferences between those with 1 versus 2 or 3 depression
riteria were not significant.
Subsequent multivariate analyses included all factors
isted in Table 1 (with the exception of the cardiovascular
vents and procedures variables). Baseline antidepressant
se and a history of depression treatment predicted adjusted
VD costs (r  0.08, r  0.09, respectively, p  0.02, p 
.006), however, BDI scores did not (r  0.02, p  0.50).
mong the measured covariates older age, higher CAD
everity scores, and nonmarried relationship status predicted
VD costs at the p  0.05 level.
epression-cardiovascular costs relationships by CAD
tatus. Of 868 women, 338 (38.9%) met criteria for signif-
cant CAD (stenosis 50%). Assessing the relationship
epression Marker (N  868)
th/Without Depression Marker (N  868)
Beck Depression Inventory >10
(n  654)
Antidepressant Use
(n  868)
Yes
(n  292)
No
(n  362)
Yes
(n  166)
No
(n  702)
56.1 (11.3) 59.3 (11.3)* 55.8 (11.3) 58.8 (11.6)*
77.4 85.4* 82.7 79.8
80.5 86.7* 81.9 81.2
25.8 11.6* 100.0 0.0
25.3 16.3 37.9 15.4*
33.6 15.3* 76.7 13.3*
100.0 0.0 64.1 40.3*
24.9 20.8 29.7 24.0
56.8 49.0 67.9 52.1*
59.7 54.3 66.3 57.8*
37.1 22.8* 43.9 30.3*
27.4 12.7* 28.3 18.2*
49.6 39.4* 51.8 47.2
49.0 45.0 58.4 46.2*
30.5 32.0 32.5 28.6
17.2 (13.8) 25.4 (14.8)* 15.7 (13.1) 21.0 (14.6)*
12.8 (11.9) 13.9 (13.6) 13.1 (12.1) 15.2 (15.2)*
57.2 67.9* 58.0 63.8
44.8 33.4* 44.2 36.6*
20.9 28.7* 19.4 26.4*
27.0 11.0* 34.0 15.0*
40.0 50.0* 34.0 37.0
8.3 12.9* 9.2 13.9*
6.3 5.1 8.1 8.5
14.0 14.5 18.6 15.6
29.1 27.3 34.8 26.9*
8.1 4.2* 8.1 6.7
6.0 1.7* 6.8 2.9*
6.3 3.6 6.8 4.2
9.8 7.5 14.3 9.9
. t tests used to compare differences in means. *p  0.05 between depression groups; †percent
TCA  percutaneous transluminal coronary angioplasty.out D
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Depression and Health Care Costs January 13, 2009:176–83AD status revealed an uneven pattern of associations. As
hown in Table 3, depressed status on any of the 3
epression markers was associated with significantly higher
ardiovascular costs among women without significant
AD, but not among women with significant CAD.
iscussion
n a sample of women with suspected myocardial isch-
mia, participants meeting criteria for depression showed
ubstantially higher cardiovascular costs. These higher
osts were present whether measured in the form of
ntidepressant use, a history of depression treatment,
r—to a slightly lesser degree— questionnaire-derived
epression symptom severity. Cardiovascular cost in-
reases were present despite evidence of less severe CAD
mong the depressed cohorts. The separate cost catego-
ies reinforce the stability of the findings, as cardiovas-
ular cost outcomes are less likely to include costs for
ental health treatment that may have artificially inflated
he medication cost differences. Secondary analyses fur-
her indicated that depression-cost relationships were
trongest among women without evidence of significant
AD. Collectively, these findings suggest that depression
s an important factor in understanding overall and
ardiovascular-related costs in symptomatic women. The
esults also support the efforts of recent interventional
tudies (38,39) showing that programs for identifying and
Figure 1 Cardiovascular Costs
Categorized by Depression Status
All depression groups differed from nondepressed women in univariate analysis
(p  0.05). Dashed line  antidepressants; solid line  depression history;
dotted line  Beck Depression Inventory 9; gray line  no depression.anaging depression can produce substantial savings. De T
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January 13, 2009:176–83 Depression and Health Care Costsowever, whether depression treatment can lower costs
pecifically in cardiac populations is untested at this time.
As an extension to previous research highlighting
epression-related cost increases in cardiac samples, an
mportant analytic aim in this study was to investigate
xplanatory mechanisms for increased costs among de-
ressed women. Toward this objective, our regression
odels included a comprehensive set of demographic,
VD risk factors, CAD severity, and other covariates,
nd these factors offered some valuable insights into the
ost relationships. Higher cardiovascular costs among
omen with elevated BDI scores, for example, were
argely explained by differences in CVD risk factors such
s smoking rates and obesity, as well as higher levels of
unctional disability in this population. In contrast, costs
mong women using antidepressants or with a history of
epression treatment remained statistically higher after
emographic and CVD risk factor adjustment. For all 3
epression definitions, the clearest pathway to increased
ealth care costs was the higher rates of CVD events
xperienced by depressed women (Table 1) despite less
evere angiographic CAD. It is also possible that the
epression treatment history and antidepressant were more
eliable predictors of costs and CVD outcomes because they
epresent more severe or enduring forms of depression.
owever, this difference may also be a result of power
ifferences in the 2 models (roughly 30% fewer women had
DI scores and dichotomization of the BDI scores). To our
nowledge, no study to date has been able to compare and
ontrast cost relationships with multiple measures of de-
ression or has provided a statistical basis for understanding
he pathways that contribute to higher costs.
The results presented in this report are consistent with
hose from a growing body of research demonstrating
ncreased medical expenses in chronic disease populations
or patients suffering from depression (17–19). For example,
ullivan et al. (18) reported relative cost increases of 26% to
9% among heart failure patients using antidepressants
ersus nondepressed patients, and Simon et al. (5) observed
0% to 75% higher costs in a diabetic sample among those
ho were also depressed based on questionnaire criteria.
any factors probably contribute to the added health care
xpenses among depressed patients. Depression is associated
ith poorer treatment adherence, poor health behavior
atterns, social isolation, and biological factors such as
levations in proinflammatory markers such as C-reactive
rotein, and hypercortisolemia (40). Further, depression is
n established predictor of cardiac event risk (6,40), a
elationship that was also observed here. Finally, mental
ealth conditions such as depression and anxiety are associated
ith higher rates of physical symptoms (41), and the Shaw et
l. (25) earlier cost analyses from the WISE sample reinforced
he need for understanding symptom-driven care patterns in
he interpretation of cardiovascular costs. The WISE protocol
as well designed for capturing the presence of a broad rangeof medical and psychiatric symptoms; however, symptomT
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Depression and Health Care Costs January 13, 2009:176–83haracteristics that were generally not included in our measure-
ent such as symptom duration or stability over time could be
mportant to explicate in future research addressing
epression-cost relationships.
tudy limitations. Health care expenses were a secondary
utcome in the WISE study. For this reason, a number of
mportant limitations were present. All 3 definitions em-
loyed in this report to estimate rates of depression in the
ISE study contain limitations to accuracy. The WISE
rotocol, for example did not include an assessment of the
lass, dose, or effectiveness of antidepressants (e.g., selective
erotonin reuptake inhibitor vs. tricyclics) prescribed among
hose reporting use at baseline. Antidepressants can be
rescribed for a variety of common medical conditions such
s insomnia and chronic pain, and for parallel mental health
onditions such as anxiety disorders.
Likewise, our assessment of depression treatment history
id not gather information concerning type of treatment,
hen the treatment occurred, or the outcome of the
reatment. The WISE women were largely of middle to
ower socioeconomic status, with limited access to insurance
o cover medication prescriptions or mental health care (25).
s a result, the primary source of depression recognition
nd treatment likely resulted from primary care physicians,
ho may underestimate rates of mental health conditions
42). On the other hand, because this was a patient group
dentified by the presence of angina and suspected myocar-
ial ischemia, depression symptom questionnaires such as
he BDI—which are heavily influenced by the presence of
hysical symptoms—probably overestimated the rates of
ctual depression in the WISE sample. Given the impreci-
ion in depression assessment, the reliability of the
epression-cost relationships we observed is surprising, and
he true relationship between these variables may be even
tronger than reported.
onclusions
epression was associated with 15% to 53% increases in
-year cardiovascular costs in a symptomatic sample of
omen, and these cost differences were only partially
xplained by a comprehensive collection of covariate pre-
ictors. Relationships between depression and costs were
articularly strong among women without evidence of
ignificant CAD, suggesting that depression may play a
arger cost role in women without traditional markers of
eart disease. The substantial published data indicates that
epression is common in cardiac populations. The current
esults corroborate rates from prior research—with depres-
ion estimates ranging from 17% to 45% using different
efinitions—and support future research testing of the
ypothesis that improved attention to diagnosing and ef-
ectively treating depression could result in reduced medical
xpenses among women with suspected CAD.eprint requests and correspondence: Dr. Thomas Rutledge,
sychology Service 116B, Veterans Affairs San Diego Healthcare
ystem, Medical Center, 3350 La Jolla Village Drive, San Diego,
alifornia 92161. E-mail: Thomas.Rutledge@va.gov.
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